What Is the Difference Between Paxlovid and Lagevrio?

Understanding the Role of Antiviral Treatments for COVID-19

Since the emergence of the SARS-CoV-2 virus, the global medical community has worked tirelessly to develop effective treatments to mitigate the impact of the disease, particularly in high-risk individuals. Among the most significant breakthroughs have been oral antiviral medications designed to reduce the severity of symptoms, lower the risk of hospitalization, and shorten recovery times. Two such treatments—Paxlovid and Lagevrio (molnupiravir)—have risen to prominence as frontline options for managing mild to moderate cases of COVID-19 in non-hospitalized patients. While both are antivirals authorized for emergency use or full approval in several countries, including the United States, they differ significantly in their mechanisms, efficacy, safety profiles, and usage guidelines.

This comprehensive article explores the key differences between Paxlovid and Lagevrio, giving patients, caregivers, and healthcare professionals the knowledge needed to make informed treatment decisions.

What Is Paxlovid?

Composition and Mechanism of Action

Paxlovid, developed by Pfizer, is a combination antiviral therapy composed of two active ingredients: nirmatrelvir and ritonavir. Nirmatrelvir is the primary antiviral agent designed to inhibit a critical enzyme known as the 3CL protease, which the SARS-CoV-2 virus needs to replicate. By blocking this enzyme, nirmatrelvir prevents the virus from making functional new copies of itself.

Ritonavir, a drug originally developed for HIV treatment, is included not for its antiviral effects against SARS-CoV-2 but to boost the levels of nirmatrelvir in the bloodstream. It does so by inhibiting liver enzymes (specifically CYP3A) that would otherwise break down nirmatrelvir too quickly. This “pharmacokinetic boosting” effect ensures that therapeutic concentrations of nirmatrelvir remain high enough in the body to effectively combat the virus.

Approved Use and Patient Eligibility

Paxlovid received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in December 2021 and was later granted full approval for treatment of mild-to-moderate COVID-19 in adults and children aged 12 years and older who are at high risk for progression to severe illness. This includes individuals with underlying conditions such as diabetes, heart disease, obesity, or compromised immune systems.

Crucially, treatment must be initiated within 5 days of symptom onset to be most effective. The standard regimen is a 5-day course, with patients taking two tablets of nirmatrelvir (150 mg)** and one tablet of ritonavir (100 mg) together twice daily.

Efficacy and Clinical Trial Results

Clinical trials have shown that Paxlovid reduces the risk of hospitalization and death by about 88% compared to placebo when administered early to high-risk individuals. This high efficacy rate has made Paxlovid the preferential first-line antiviral treatment in many clinical guidelines. Real-world studies have reinforced this finding, though slightly lower effectiveness has been observed in certain populations—such as vaccinated or immunocompetent patients—which underscores the importance of timely administration.

Side Effects and Safety Profile

Common side effects associated with Paxlovid include:

• Altered taste (dysgeusia)
• Nausea
• Diarrhea
• Increased blood pressure
• Muscle aches

More importantly, Paxlovid is known for its potential to cause drug-drug interactions because of ritonavir’s effect on liver metabolism. It can interfere with blood thinners, antiarrhythmics, statins, and certain mental health medications. As a result, healthcare providers must carefully review a patient’s complete medication list before prescribing Paxlovid. In some cases, Paxlovid may require temporary discontinuation of other drugs during treatment.

What Is Lagevrio (Molnupiravir)?

Composition and Mechanism of Action

Lagevrio, marketed by Merck and Ridgeback Biotherapeutics, contains the active ingredient molnupiravir. Unlike Paxlovid, which blocks viral replication through enzyme inhibition, molnupiravir works by introducing errors into the virus’s genetic material. When the SARS-CoV-2 virus uses RNA to copy itself, molnupiravir mimics one of the essential building blocks of RNA—specifically, cytidine and uridine.

Once incorporated into the viral RNA, molnupiravir causes frequent mutations during replication. Over time, the accumulation of errors renders the virus non-infectious or unable to replicate effectively—a process known as “error catastrophe” or “lethal mutagenesis.”

Approved Use and Patient Eligibility

Lagevrio received EUA in the United States in December 2021 and is indicated for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progressing to severe disease and who have limited alternative treatment options. It is generally considered a second-line option.

Like Paxlovid, Lagevrio treatment must begin within 5 days of symptom onset. The prescribed dosage is one 200 mg capsule taken orally twice daily for 5 consecutive days.

Efficacy and Clinical Trial Results

The MOVe-OUT phase 3 clinical trial demonstrated that Lagevrio reduced the risk of hospitalization or death by approximately 30% relative to placebo in unvaccinated, at-risk adults. While this is a significant benefit—especially in reducing severe outcomes—it is notably lower than Paxlovid’s reduction of around 88%. This diminished efficacy influenced regulatory and clinical guidance to reserve Lagevrio primarily for patients who cannot use Paxlovid due to drug interactions, contraindications, or allergic responses.

Subsequent real-world studies have reported mixed efficacy results, with some suggesting even lower effectiveness, especially in vaccinated populations. This has led to ongoing debate about the optimal use cases for molnupiravir.

Side Effects and Safety Profile

Common side effects of Lagevrio include:

• Dizziness
• Nausea
• Diarrhea

One of the primary safety concerns with molnupiravir is its mechanism of action: because it damages viral RNA by causing mutations, there is theoretical concern it could also affect human DNA, especially in rapidly dividing cells. Although studies suggest that molnupiravir has a low risk of damaging human cells, it is not recommended for use in children or pregnant individuals due to potential risks to bone and cartilage development and fetal harm.

Additionally, Lagevrio is contraindicated during pregnancy, and both men and women are advised to use effective contraception during and after treatment. Breastfeeding is also discouraged during and for a few days after treatment.

Key Differences Between Paxlovid and Lagevrio

1. Mechanism of Action

The most fundamental difference between the two medications lies in how they combat the virus:

• Paxlovid works by inhibiting a specific viral enzyme (3CL protease), stopping replication at the protein-processing stage.
• Lagevrio disrupts viral replication by corrupting the virus’s genetic code, causing irreversible mutations.

This distinction is not merely academic—it has downstream consequences for efficacy, safety, and resistance potential.

2. Efficacy in Clinical Trials

When comparing head-to-head clinical trial data, the difference in effectiveness is stark:

1. Paxlovid: ~88% reduction in hospitalization and death
2. Lagevrio: ~30% reduction in hospitalization and death

This makes Paxlovid significantly more effective in preventing disease progression, particularly in unvaccinated and older adult populations. The higher efficacy has established Paxlovid as the preferred first-line therapy when suitable.

3. Safety and Use in Special Populations

Each drug presents unique safety challenges:

• Paxlovid poses a high risk of drug interactions due to ritonavir’s effect on CYP450 enzymes. It must be used cautiously in patients with kidney impairment and is not recommended for those with severe renal or hepatic disease.
• Lagevrio is excluded from use in pregnant or potentially pregnant individuals and those under 18 due to potential mutagenicity and impact on development. While drug interactions are less of a concern, safety monitoring is still necessary.

4. Availability and Treatment Guidance

Many health authorities, including the U.S. Centers for Disease Control and Prevention (CDC) and the Infectious Diseases Society of America (IDSA), recommend Paxlovid as the treatment of choice for eligible patients. Lagevrio is typically suggested only when Paxlovid is contraindicated.

A practical decision tree often used by clinicians looks like this:

5. Resistance and Long-Term Implications

Preliminary research suggests that molnupiravir-induced mutations might, in theory, contribute to the emergence of new viral variants if used widely—though real-world evidence of this remains minimal. In contrast, Paxlovid has not been associated with increased viral mutation risk. However, rare cases of viral rebound—where symptoms return after treatment—have been observed with Paxlovid. These rebounds do not indicate drug resistance but may affect transmission risk.

Real-World Use and Public Health Considerations

While clinical trial data provide a strong foundation, real-world effectiveness is equally important. In the post-vaccination era, the benefits of both medications have somewhat diminished but remain significant, particularly in elderly and immunocompromised populations.

Accessibility and Cost

Both medications are covered by most U.S. insurance plans, including Medicare, and are available free of charge through federal programs such as the Test-to-Treat initiative. Paxlovid, however, has seen broader distribution and higher acceptance due to its superior efficacy, while Lagevrio is often stocked as a backup option.

Patient Adherence and Convenience

Both medications require twice-daily dosing over five days, making their dosing schedules comparable. However, patients on Paxlovid might need to alter or pause other medications, which can complicate treatment adherence. Lagevrio’s fewer drug interactions may make it easier to administer in polypharmacy patients, but the stringent reproductive safety requirements may limit willingness to use it.

Rebound Phenomenon with Paxlovid

A notable concern with Paxlovid is the “rebound” effect, where some patients experience a return of symptoms or retest positive after completing treatment. Studies suggest this occurs in approximately 5-10% of cases, but most individuals do not require hospitalization during rebound episodes. Importantly, rebound does not appear to indicate a failure of antiviral activity or the development of resistant virus strains.

Lagevrio has not been frequently associated with viral rebound, though data are limited. The reason for this difference is still under investigation.

When Should You Consider Each Treatment?

Choose Paxlovid If:

• You are at high risk for severe COVID-19.
• You do not have contraindications to ritonavir or significant drug interactions.
• You want the most effective available treatment.
• You are not pregnant or trying to become pregnant.

Paxlovid is particularly recommended for individuals over 50 with comorbidities or those who are immunocompromised.

Choose Lagevrio If:

• Paxlovid is not an option due to drug interactions.
• You cannot access Paxlovid in time.
• You understand and can follow contraception protocols (if applicable).
• You are not pregnant and do not plan to become pregnant in the near term.

It’s important to note that neither drug replaces vaccination. Vaccination remains the most effective strategy to prevent severe illness, hospitalization, and death from COVID-19.

Comparative Summary

Looking Ahead: The Future of Oral Antivirals

The development of Paxlovid and Lagevrio marks a milestone in pandemic preparedness. As the global response to COVID-19 shifts toward long-term management, the need for convenient, high-efficacy treatments remains. Researchers are already working on next-generation antivirals with higher potency, fewer interactions, and broader variant coverage.

Meanwhile, access to these existing treatments must be expanded, particularly in underserved and rural communities. Telehealth programs, expanded pharmacy prescribing, and enhanced public education can help high-risk individuals receive timely care.

Conclusion

In the battle against mild to moderate COVID-19, Paxlovid and Lagevrio serve as powerful tools—but they are not interchangeable. Paxlovid is more effective and widely recommended as the first-line treatment for high-risk patients. Its use comes with important caveats, including a high potential for medication interactions, which require careful management.

Lagevrio offers a valuable alternative when Paxlovid cannot be used, but its lower efficacy and significant reproductive safety concerns limit its role. Decision-making should always involve a thorough evaluation of patient-specific factors, including medical history, current medications, pregnancy status, and access to care.

Ultimately, early diagnosis followed by prompt antiviral treatment—whether Paxlovid or Lagevrio—can make a substantial difference in patient outcomes. However, these medications work best as part of a broader strategy that includes vaccination, testing, and public health awareness.

If you or someone you know tests positive for COVID-19 and falls into a high-risk category, contact a healthcare provider immediately to discuss eligibility for antiviral therapy. Timing is critical—starting treatment early is key to preventing severe illness and saving lives.

What are Paxlovid and Lagevrio, and how are they used to treat COVID-19?

Paxlovid and Lagevrio are antiviral medications authorized for the treatment of mild to moderate COVID-19 in individuals at high risk of progressing to severe illness. Paxlovid is a combination of two drugs: nirmatrelvir and ritonavir. Nirmatrelvir inhibits a key SARS-CoV-2 enzyme necessary for viral replication, while ritonavir slows the breakdown of nirmatrelvir, allowing it to remain active in the body longer. Lagevrio, also known as molnupiravir, works differently by introducing errors into the virus’s genetic code during replication, ultimately preventing the virus from multiplying effectively.

Both medications are designed to be taken orally, usually within the first five days of symptom onset, and are intended to reduce the risk of hospitalization and death from COVID-19. They are not substitutes for vaccination but serve as therapeutic options for those who become infected. Paxlovid is generally preferred over Lagevrio due to its higher efficacy, but Lagevrio may be used when Paxlovid is contraindicated, such as in patients taking medications that interact dangerously with ritonavir. The choice between the two depends on individual patient factors, including comorbidities and drug interactions.

How effective are Paxlovid and Lagevrio in preventing severe outcomes from COVID-19?

Clinical trials have shown that Paxlovid is highly effective in reducing the risk of hospitalization and death in high-risk individuals. In its pivotal trial, Paxlovid demonstrated an 88% reduction in the risk of hospitalization or death compared to placebo when administered within five days of symptom onset. This significant efficacy has positioned Paxlovid as a leading treatment option for early-stage COVID-19, especially among unvaccinated or immunocompromised patients who are more vulnerable to severe disease.

In contrast, Lagevrio has shown more modest effectiveness. In its Phase 3 trial, molnupiravir reduced the risk of hospitalization or death by approximately 30% compared to placebo, a lower efficacy rate than Paxlovid. Due to this difference, health authorities often recommend Paxlovid as the first-line antiviral when appropriate. However, Lagevrio remains a valuable alternative for patients who cannot take Paxlovid due to drug interactions or other contraindications. Both drugs underscore the importance of early treatment to maximize their benefits.

What are the key differences in how Paxlovid and Lagevrio work in the body?

Paxlovid functions by targeting a specific viral protease enzyme, 3CL protease, which the SARS-CoV-2 virus needs to process proteins and replicate. Nirmatrelvir, one component of Paxlovid, binds directly to this enzyme and inhibits its activity, effectively halting the virus’s ability to mature and spread. The addition of ritonavir, a pharmacokinetic enhancer, boosts nirmatrelvir levels by slowing its metabolism in the liver, thereby prolonging its antiviral effect. This mechanism allows Paxlovid to effectively suppress viral load during the early stages of infection.

Lagevrio operates through a different mechanism called lethal mutagenesis. It works by mimicking a nucleoside, a building block of RNA, and is incorporated into the virus’s genetic material during replication. This results in an accumulation of mutations in the viral genome, rendering the virus unable to replicate properly and leading to its collapse. Unlike Paxlovid, Lagevrio does not rely on boosting by a secondary agent and is administered as a single compound. Its mode of action is more error-prone and can affect other RNA viruses, but it’s less potent than Paxlovid’s targeted inhibition.

Are there significant differences in side effects between Paxlovid and Lagevrio?

Paxlovid is generally well-tolerated, but common side effects include altered taste (dysgeusia), diarrhea, high blood pressure, and muscle aches. Some patients also report gastrointestinal discomfort. A more critical concern with Paxlovid is its potential for drug interactions, primarily due to ritonavir, which affects liver enzymes involved in metabolizing many other medications. This means patients on certain drugs—such as blood thinners, statins, or antiarrhythmics—may need to adjust or temporarily stop them during treatment, requiring close medical supervision.

Lagevrio tends to have fewer reported drug interactions, making it a safer option for patients on multiple medications. Its most common side effects are mild and include diarrhea, nausea, dizziness, and headache. However, there are theoretical concerns about Lagevrio’s mechanism of action, as it introduces mutations into RNA, potentially raising questions about long-term safety, including effects on human DNA in rare cases, although current evidence has not shown such risks in clinical use. Due to these concerns, Lagevrio is not recommended for use during pregnancy or for children under 18.

Who is eligible to take Paxlovid versus Lagevrio?

Paxlovid is authorized for adults and pediatric patients (12 years and older, weighing at least 40 kg) who have tested positive for SARS-CoV-2 and are at high risk for progression to severe illness. This includes individuals with underlying conditions such as diabetes, heart disease, obesity, or immunosuppression. However, Paxlovid is not recommended for patients with severe kidney or liver impairment, and caution is needed for those taking medications that strongly interact with ritonavir. A thorough medication review is essential before prescribing.

Lagevrio is also authorized for adults with mild to moderate COVID-19 who are at high risk for severe outcomes, but it is not authorized for use in children under 18 due to potential risks to bone and cartilage development. It is generally considered an alternative when Paxlovid cannot be used. Lagevrio is contraindicated during pregnancy because of concerns about fetal development, and both men and women of reproductive potential are advised to use contraception during and after treatment. The selection between the two depends on individual health profiles and medication regimens.

How are Paxlovid and Lagevrio prescribed and administered?

Paxlovid is administered as three tablets taken together—two of nirmatrelvir and one of ritonavir—twice daily for five consecutive days, totaling 30 tablets for a full course. It must be started as soon as possible after diagnosis and within five days of symptom onset to be effective. Because of ritonavir’s interaction with numerous other drugs, a healthcare provider typically reviews the patient’s full medication list to avoid harmful interactions. Pharmacies often provide detailed counseling to ensure proper use.

Lagevrio is taken as four 200 mg capsules, totaling 800 mg, twice daily for five days, resulting in 40 capsules for the treatment course. Like Paxlovid, it must be initiated within five days of symptom onset. The dosing is simpler than Paxlovid in terms of drug interaction management, though treatment adherence is crucial. Prescriptions for both medications are provided following a confirmed diagnosis of COVID-19 and a clinical evaluation of risk factors. Access may depend on regional availability and healthcare guidelines.

Can Paxlovid and Lagevrio be used as preventive treatments for COVID-19?

Neither Paxlovid nor Lagevrio are approved for pre-exposure or post-exposure prevention of COVID-19. They are strictly authorized for treatment after an individual has tested positive and is experiencing symptoms, particularly for those at higher risk of severe disease. These antivirals are not intended to replace preventive measures such as vaccination, masking, or social distancing. Their effectiveness is tied to early intervention during active infection, not in blocking the virus before it takes hold.

Research into the preventive use of antivirals like Paxlovid is ongoing, but current evidence does not support their use for prophylaxis. For example, some studies are exploring Paxlovid in high-risk household contacts, but no definitive recommendations have been made. Lagevrio’s use remains strictly treatment-focused due to its lower efficacy and safety concerns. The gold standard for preventing severe outcomes from COVID-19 continues to be vaccination, with antivirals playing a key role only after infection occurs.